ANXA5 and breast carcinoma: Our data attested that B1 AMCE is capable of suppressing the tumor growth in the 4 T1 breast cancer in murine tumor models (after 28 days of treatment) based on the regression of weight and volume of the tumors, in agreement with the in vitro assays (MTT, Annexin V/FITC, AO/PI, cell cycle analysis) results.